Cellular mechanisms and second messengers: Relevance to the psychopharmacology of bipolar disorders

International Journal of Neuropsychopharmacology

Volumn 6, Issue 2, 2003, Pages 181-189

  Brunello, Nicoletta ^a   Tascedda, Fabio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Gene expression; Lithium; Mood stabilizers; Second messengers

Indexed keywords

LITHIUM; VALPROIC ACID;

BIPOLAR DISORDER; BLOOD ANALYSIS; CELL ACTIVITY; CEREBROSPINAL FLUID; DRUG EFFECT; HUMAN; ION TRANSPORT; MOLECULAR INTERACTION; NEUROBIOLOGY; NEUROTRANSMISSION; PRIORITY JOURNAL; REVIEW; SECOND MESSENGER;

ANIMALS; BIPOLAR DISORDER; HUMANS; SECOND MESSENGER SYSTEMS;

EID: 0038383690     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145703003419     Document Type: Review

References (63)

1. Asghari V, Wang JF, Reiach JS, Young LT (1998). Differential effects of mood stabilizers on Fos/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY5Y cells. Molecular Brain Research 58, 95-102.
2. Brambilla P, Barale F, Soares JC (2001). Perspectives on the use of anticonvulsants in the treatment of bipolar disorder. International Journal of Neuropsychopharmacology 4, 421-446.
3. Casebolt TL, Jope RS (1991). Effects of chronic lithium treatment on protein kinase C and cyclic AMP-dependent protein phosphorylation. Biological Psychiatry 29, 233-243.
4. Chen G, Hawver D, Wright C, Potter WZ, Manji HK (1996). Attenuation of adenylate cyclases by carbamazepine in vitro. Journal of Neurochemistry 67, 2079-2086.
5. Chen G, Hasanat KA, Bebchuk J, Moore G, Glitz D, Manji HK (1999a). Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosomatic Medicine 61, 599-617.
6. Chen G, Huang L-D, Jiang Y-M, Manji HK (1999d). The mood stabilizing agent valproate inhibits the activity of glycogen synthase kinase 3. Journal of Neurochemistry 72, 1327-1330.
7. Chen G, Manji HK, Hawver DB, Wright CB, Potter WZ (1994). Chronic sodium valproate selectively decreases protein kinase C α and ε in vitro. Journal of Neurochemistry 63, 2361-2364.
8. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK (2000). Enhancement of hippocampal neurogenesis by lithium. Journal of Neurochemistry 75, 1729-1734.
9. Chen G, Yuan P-X, Hawver D, Potter WZ, Manji HK (1997). Increase in AP-1 transcription factor DNA binding activity by valproic acid. Neuropsychopharmacology 16, 238-245.
10. Chen G, Yuan P-X, Jiang Y-M, Huang L-D, Manji HK (1999c). Valproate robustly enhances AP-1 mediated gene expression. Molecular Brain Research 64, 52-58.
11. Chen G, Zeng W-Z, Yuan P-X, Huang L-D, Jiang Y-M, Zhao Z-H, Manji HK (1999b). The mood stabilizing agents lithium and valproate robustly increase the expression of the neuroprotective protein bcl-2 in the CNS. Journal of Neurochemistry 72, 879-882.
12. Chen R-W, Chuang D-M (1999). Long term lithium treatment suppresses p53 and Bax expression but increases bcl-2 expression. Journal of Biological Chemistry 274, 6039-6042.
13. Chengappa KNR, Rathore D, Levine J, Atzert R, Solai L, Parepally H, Moffa N, Delaney J, Brar JS (1999). Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disorders 1, 42-53.
14. Chuang D-M, Chen R-W, Chalecka-Franaszek E, Ren M, Hashimoto R, Senatorov V, Kanai H, Hough C, Hiroi T, Leeds P (2002). Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disorders 4, 129-136.
15. Drevets W, Gadde K, Krishnan K (1999). Neuroimaging studies of mood disorders. In: Charney D, Nestler E, Bunney B (Eds.), Neurobiology of Mental Illness (pp. 394-418). New York: Oxford University Press.
16. Drevets WC (2000). Neuroimaging studies of mood disorders. Biological Psychiatry 48, 813-828.
17. Garlow SJ, Musselman DL, Nemeroff CB (1999). The neurochemistry of mood disorders. Clinical studies. In: Charney DS, Nester EJ, Bunney BS (Eds.), Neurobiology of Mental Illness (pp. 348-364). New York: Oxford University Press.
18. Hong M, Chen DCR, Klein PS, Lee VMY (1997). Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. Journal of Biological Chemistry 272, 25326-25332.
19. Johannessen CU (2000). Mechanisms of action of valproate: a commentatory. Neurochemistry International 37, 103-110.
20. Jope RS (1999). Anti-bipolar therapy: mechanism of action of lithium. Molecular Psychiatry 4, 117-128.
21. Jope RS, Song L, Li PP, Young LT, Kish SJ, Pacheco MA, Warsh JJ (1996). The phosphoinositide signal transduction system is impaired in bipolar affective disorder brain. Journal of Neurochemistry 66, 2402-2409.
22. Jope RS, Williams MB (1994). Lithium and brain signal transduction systems. Biochemical Pharmacology 77, 429-441.
23. Kwan P, Sills GJ, Brodie MJ (2001). The mechanisms of action of commonly used antiepileptic drugs. Pharmacology and Therapeutics 90, 21-34.
24. Lenox RH, Hahn CG (2000). Overview of the mechanism of action of lithium in the brain: fifty-year update. Journal of Clinical Psychiatry 61 (Suppl. 9), 5-15.
25. Lenox RH, McNamara RK, Papke RL, Manji HK (1998). Neurobiology of lithium: an update. Journal of Clinical Psychiatry 59 (Suppl. 6), 37-47.
26. Lenox RH, Watson DG, Ellis J (1992). Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Research 570, 333-340.
27. Li PP, Andreopoulos S, Warsh JJ (2000). Signal transduction abnormalities in bipolar affective disorder. In: Reith MEA (Ed.), Cerebral Signal Transduction (pp. 283-312). New Jersey: Humana Press.
28. Löscher W (1999). Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Progress in Neurobiology 58, 31-59.
29. Manji H, Lenox R (2000). Signaling: cellular insights into the pathophysiology of bipolar disorder. Biological Psychiatry 48, 518-530.
30. Manji HK, Bebchuk JM, Moore, GJ, Glitz D, Hasanat KA, Chen G (1999a). Modulation of CNS signal transduction pathways and gene expression by mood stabilizing agents: therapeutic implications. Journal of Clinical Psychiatry 60 (Suppl. 2), 27-39.
31. Manji HK, Chen G, Risby ED, Masana MI, Hsiao JK, Potter WZ (1996). Regulation of signal transduction pathways by mood stabilizing agents: implications for the delayed onset of therapeutic efficacy. Journal of Clinical Psychiatry 57, 34-46.
32. Manji HK, Drevets WC, Charney DS (2001). The cellular neurobiology of depression. Nature Medicine 7, 541-547.
33. Manji HK, Moore GJ, Chen G (1999b). Lithium at 50: have the neuroprotective effects of this unique medication been overlooked? Biological Psychiatry 46, 929-940.
34. Manji HK, Moore GJ, Chen G (2000a). Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. Journal of Clinical Psychiatry 61 (Suppl. 9), 82-96.
35. Manji HK, Moore GJ, Chen G (2000b). Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biological Psychiatry 48, 740-754.
36. Manji HK, Potter WZ, Lenox RH (1995). Signal transduction pathways: molecular targets for lithium's actions. Archives of General Psychiatry 52, 531-543.
37. Masana MI, Bitran JA, Hsiao JK, Potter WZ (1992). In vivo evidence that lithium inactivates Gi modulation of adenylate cyclase in brain. Journal of Neurochemistry 59, 200-205.
38. McElroy SL, Soutullo CA, Keck Jr. PE, Kmetz GF (1997). A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. Annals of Clinical Psychiatry 9, 99-103.
39. Moore G, Bebchuk J, Hasanat K, Chen G, Seraji-Bozorgzad N, Wilds IB, Faulk MW, Koch S, Glitz DA, Jolkovsky L, Manji HK (2000b). Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biological Psychiatry 48, 1-8.
40. Moore G, Bebchuk J, Wilds I, Chen G, Manji HK (2000a). Lithium therapy increases grey matter volume. Lancet 356, 1241-1242.
41. Mori S, Tardito D, Dorigo A, Zanardi R, Smeraldi E, Racagni G, Perez J (1998). Effects of lithium on cAMP-dependent protein kinase in rat brain. Neuropsychopharmacology 19, 233-240.
42. Mori S, Zanardi R, Popoli M, Smeraldi E, Racagni G, Perez J (1996). Inhibitory effect of lithium on cAMP dependent phosphorylation system. Life Sciences 59, 99-104.
43. Müller-Oerlinghausen B, Berghöfer A, Bauer M (2002). Bipolar disorder. Lancet 359, 241-247.
44. Nonaka S, Chuang D (1998). Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. NeuroReport 9, 2081-2084.
45. Ozaki N, Chuang D-M (1997). Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. Journal of Neurochemistry 69, 2336-2344.
46. Perez J, Tardito D, Mori S, Racagni G, Smeraldi E, Zanardi R (1999). Abnormalities of cyclic adenosine monophosphate signaling in platelets from untreated patients with bipolar disorder. Archives of General Psychiatry 56, 248-253.
47. Perez J, Tardito D, Mori S, Racagni G, Smeraldi E, Zanardi R (2000). Abnormalities of cAMP signaling in affective disorders: implications for pathophysiology and treatment. Bipolar Disorders 2, 27-36.
48. Shaldubina A, Agam G, Belmaker RH (2001). The mechanism of lithium action: state of the art, ten years later. Progress in Neuro-Psychopharmacology and Biological Psychiatry 5, 855-866.
49. Soares JC, Mallinger AG (1997). Intracellular phosphatidylinositol pathway abnormalities in bipolar disorder patients. Psychopharmacology Bulletin 33, 685-691.
50. Sporn J, Sachs G (1997). The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. Journal of Clinical Psychopharmacology 17, 185-189.
51. Stabel S, Parker PJ (1991). Protein kinase C. Pharmacology and Therapeutics 51, 71-95.
52. Stambolic V, Laurent RR, Woodgett JR (1996). Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Current Biology 6, 1664-1668.
53. Thase ME, Sachs G (2000). Bipolar depression: pharmacotherapy and related therapeutic strategies. Biological Psychiatry 48, 558-572.
54. Vawter MP, Freed WJ, Kleinman JE (2000). Neuropathology of bipolar disorder. Biological Psychiatry 48, 486-504.
55. Wang HY, Friedman E (1996). Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biological Psychiatry 40, 568-575.
56. Warsh JJ, Li PP (1996). Second messenger systems and mood disorders. Current Opinion in Psychiatry 9, 23-29.
57. Warsh JJ, Young LT, Li PP (2000). Guanine nucleotide binding (G) protein disturbances in bipolar affective disorder. In: Manji HK, Bowden CL, Belmaker RH (Eds.), Bipolar Medications: Mechanisms of Action (pp. 299-329). Washington, DC: American Psychiatric Press.
58. Watson DG, Watterson JM, Lenox RH (1998). Sodium valproate downregulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells: a property of protein kinase C-mediated mood stabilizers. Journal of Pharmacology and Experimental Therapeutics 285, 307-316.
59. Williams R, Harwood A (2000). Lithium therapy and signal transduction. Trends in Pharmacological Sciences 21, 61-64.
60. Young LT, Li PP, Kish SJ, Siu KP, Kamble A, Hornykiewicz O, Warsh JJ (1993). Cerebral cortex Gs alpha protein levels and forskolin-stimulated cyclic AMP formation are increased in bipolar affective disorder. Journal of Neurochemistry 61, 890-898.
61. Yuan P-X, Chen G, Huang L-D, Manji HK (1998). Lithium stimulates gene expression through the AP-1 transcription factor pathway. Molecular Brain Research 58, 225-230.
62. Yuan PX, Huong LD, Jiang YM, Gutkind JS, Manji HK, Chen G (2001). The mood-stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. Journal of Biological Chemistry 276, 31674-31683.
63. Zanardi R, Racagni G, Smeraldi E, Perez J (1997). Differential effects of lithium on platelet protein phosphorylation in bipolar patients and healthy subjects. Psychopharmacology 129, 44-47.